Clinical Trial Update: Study in Japan and Ex-Japan to Characterize the Pharmacokinetic and Pharmacodynamic Response to Orteronel (TAK-700) in Chemotherapy-Naive Participants With Castration-Resistant Prostate Cancer [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 study assessing the pharmacokinetic and pharmacodynamic response to Orteronel (TAK-700) in chemotherapy-naive patients with castration-resistant prost…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• Orteronel (Orteronel)

Snippet

Sponsor: Millennium Pharmaceuticals, Inc. | Conditions: Prostate Cancer | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2018-03-20